Study of Single Nucleotide Polymorphisms of FBW7 and Its Substrate Genes Revealed a Predictive Factor for Paclitaxel Plus Cisplatin Chemotherapy in Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Jun 4

PMID 27259248

Citations 2

Authors

Ying Liu

Shu Ning Xu

Yong Shun Chen

Xiao Yuan Wu

Lei Qiao

Ke Li

Long Yuan

Affiliations

Soon will be listed here.

Abstract

Paclitaxel plays a major role in the treatment of advanced esophageal squamous cell carcinoma. However, there is no biomarker that could be used to predict the clinical response of paclitaxel. This work was conducted to investigate the association of genetic polymorphisms in FBW7 and its substrate genes and the clinical response of paclitaxel. Patients with advanced esophageal squamous cell carcinoma were treated with paclitaxel 175 mg/m2 over 3 hours day 1 and cisplatin 75 mg/m2 day 1, every 3 weeks. The genotypes of 11 FBW7 and its substrate gene polymorphisms were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Statistical analysis revealed that patients with mTOR rs1057079 AG (ORadjusted: 4.59; 95% CI: 1.78-11.86) genotype had significant correlation with the clinical response of paclitaxel when compared with AA genotype after adjustment for sex, age, and chemotherapy cycle. The median progression-free survival (PFS) of patients with advanced ESCC who received paclitaxel plus cisplatin (TP) as first-line treatment is 14.3 months (95% CI: 9.0-19.60 months). The median PFS (mPFS) of AG genotypes and AA genotypes in mTOR rs1057079 were 17.31 months (95% CI: 15.9-18.67 months) and 9.8 months (95% CI: 8.58-11.02 months) (p=0.019), respectively.

Citing Articles

FBW7 Regulates the Autophagy Signal in Mesangial Cells Induced by High Glucose.

Gao C, Fan F, Chen J, Long Y, Tang S, Jiang C Biomed Res Int. 2019; 2019:6061594.

PMID: 31119177 PMC: 6500712. DOI: 10.1155/2019/6061594.

Genetic polymorphisms of Wnt/β-catenin pathway genes are associated with the efficacy and toxicities of radiotherapy in patients with nasopharyngeal carcinoma.

Yu J, Huang Y, Liu L, Wang J, Yin J, Huang L Oncotarget. 2016; 7(50):82528-82537.

PMID: 27769064 PMC: 5347711. DOI: 10.18632/oncotarget.12754.

References

Sundqvist A, Bengoechea-Alonso M, Ye X, Lukiyanchuk V, Jin J, Harper J . Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab. 2005; 1(6):379-91. DOI: 10.1016/j.cmet.2005.04.010. View

Zhu J, Wang M, Zhu M, He J, Wang J, Jin L . Associations of PI3KR1 and mTOR polymorphisms with esophageal squamous cell carcinoma risk and gene-environment interactions in Eastern Chinese populations. Sci Rep. 2015; 5:8250. PMC: 4318264. DOI: 10.1038/srep08250. View

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

Finkin S, Aylon Y, Anzi S, Oren M, Shaulian E . Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy. Oncogene. 2008; 27(32):4411-21. DOI: 10.1038/onc.2008.77. View

Zhao D, Zheng H, Zhou Z, Chen C . The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. Cancer Res. 2010; 70(11):4728-38. DOI: 10.1158/0008-5472.CAN-10-0040. View

Kavallaris M . Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010; 10(3):194-204. DOI: 10.1038/nrc2803. View

Minella A, Clurman B . Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle. 2005; 4(10):1356-9. DOI: 10.4161/cc.4.10.2058. View

Wu X, Gu J, Wu T, Swisher S, Liao Z, Correa A . Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006; 24(23):3789-98. DOI: 10.1200/JCO.2005.03.6640. View

Rocher-Ros V, Marco S, Mao J, Gines S, Metzger D, Chambon P . Presenilin modulates EGFR signaling and cell transformation by regulating the ubiquitin ligase Fbw7. Oncogene. 2010; 29(20):2950-61. PMC: 4162408. DOI: 10.1038/onc.2010.57. View

10.

Welcker M, Clurman B . FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2007; 8(2):83-93. DOI: 10.1038/nrc2290. View

11.

Polee M, Eskens F, van der Burg M, Splinter T, Siersema P, Tilanus H . Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer. 2002; 86(5):669-73. PMC: 2375296. DOI: 10.1038/sj.bjc.6600166. View

12.

Punga T, Bengoechea-Alonso M, Ericsson J . Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding. J Biol Chem. 2006; 281(35):25278-86. DOI: 10.1074/jbc.M604983200. View

13.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C . Cancer statistics, 2006. CA Cancer J Clin. 2006; 56(2):106-30. DOI: 10.3322/canjclin.56.2.106. View

14.

Minella A, Welcker M, Clurman B . Ras activity regulates cyclin E degradation by the Fbw7 pathway. Proc Natl Acad Sci U S A. 2005; 102(27):9649-54. PMC: 1172263. DOI: 10.1073/pnas.0503677102. View

15.

Wei W, Jin J, Schlisio S, Harper J, Kaelin Jr W . The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell. 2005; 8(1):25-33. DOI: 10.1016/j.ccr.2005.06.005. View

16.

Huang J, Zhou Y, Zhang H, Qu T, Mao Y, Zhu H . A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Med Oncol. 2012; 30(1):343. DOI: 10.1007/s12032-012-0343-4. View

17.

Vestermark L, Sorensen P, Pfeiffer P . [Chemotherapy to patients with metastatic carcinoma of the esophagus and gastro-esophageal junction. A survey of a Cochrane review]. Ugeskr Laeger. 2008; 170(8):633-6. View

18.

Fu L, Kim Y, Wang X, Wu X, Yue P, Lonial S . Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res. 2009; 69(23):8967-76. PMC: 2789206. DOI: 10.1158/0008-5472.CAN-09-2190. View

19.

Baird R, Tan D, Kaye S . Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol. 2010; 7(10):575-82. DOI: 10.1038/nrclinonc.2010.120. View

20.

Wertz I, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson D . Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011; 471(7336):110-4. DOI: 10.1038/nature09779. View